Joseph Bondy-Denomy is a Professor in the Department of Microbiology & Immunology at the University of California, San Francisco. Prior to coming to UCSF, Joe was a PhD student with Alan Davidson at the University of Toronto and received his undergraduate degree in Biology from the University of Waterloo. The lab is focused on studying the interactions between bacteriophages and the defense systems encoded by host bacteria, specifically focused on the human pathogen Pseudomonas aeruginosa. Historically, the lab has studied CRISPR-Cas systems and their inhibitors, anti-CRISPR proteins. More recent work has broadened that interest to include unique mechanisms of CRISPR-Cas evasion, such as “phage nucleus” compartments. The lab has also begun to characterize the immunity and anti-immunity mechanisms of Gabija, CBASS, Thoeris, Shango, and Jumbo phage killer defenses. Work in the Bondy-Denomy lab has been funded by the NIH, DARPA, the Searle Scholars Program, the Vallee Foundation, and the Innovative Genomics Institute. Dr. Bondy-Denomy serves as a reviewer for the NIH and other granting agencies and for many journals. Joe is also the co-founder of Acrigen Biosciences, a gene editing company using anti-CRISPR proteins and on the SAB of SNIPR Biome, Leapfrog Bio, and Excision Biotherapeutics.